Treatment and trials in non-metastatic castration-resistant prostate cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment and trials in non-metastatic castration-resistant prostate cancer
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-17
DOI
10.1038/s41585-021-00470-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
- (2021) Fred Saad et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
- (2020) Silke Gillessen et al. EUROPEAN UROLOGY
- Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
- (2020) Eric Jay Small et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
- (2020) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
- (2019) Bertrand Tombal et al. LANCET ONCOLOGY
- Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography.
- (2019) Christian Zurth et al. JOURNAL OF CLINICAL ONCOLOGY
- A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges
- (2019) Indu Kohaar et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?
- (2019) Celestia Higano Nature Reviews Urology
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
- (2019) Meghan A. Rice et al. Frontiers in Oncology
- Abiraterone acetate in the treatment of prostate cancer
- (2018) Abhimanyu Thakur et al. BIOMEDICINE & PHARMACOTHERAPY
- Profiling Prostate Cancer Therapeutic Resistance
- (2018) Cameron Wade et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography.
- (2018) Christian Zurth et al. JOURNAL OF CLINICAL ONCOLOGY
- The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer
- (2018) Charles J. Ryan et al. JOURNAL OF UROLOGY
- Androgen Receptor–Targeted Treatments for Prostate Cancer: 35 Years’ Progress with Antiandrogens
- (2018) E. David Crawford et al. JOURNAL OF UROLOGY
- Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms
- (2018) Heather J. Chalfin et al. JOURNAL OF UROLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of non-metastatic castrate-resistant prostate cancer: a systematic review
- (2018) Yohann Loriot et al. CANCER TREATMENT REVIEWS
- Managing Nonmetastatic Castration-resistant Prostate Cancer
- (2018) Joaquin Mateo et al. EUROPEAN UROLOGY
- Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
- (2018) Fred Saad et al. LANCET ONCOLOGY
- The role of ketoconazole in current prostate cancer care
- (2018) Vaibhav Patel et al. Nature Reviews Urology
- Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
- (2018) Vincenzo Di Nunno et al. Frontiers in Oncology
- Role of Androgen Receptor in Prostate Cancer: A Review
- (2018) Kazutoshi Fujita et al. World Journal of Mens Health
- Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer—The Forgotten Dance Partner?
- (2018) Zachary Klaassen et al. JAMA Oncology
- Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
- (2017) Wanling Xie et al. JOURNAL OF CLINICAL ONCOLOGY
- Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis
- (2016) Sohita Dhillon DRUGS
- Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer
- (2016) Thomas Pyka et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
- (2016) Matthew R. Smith et al. EUROPEAN UROLOGY
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
- (2016) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
- (2016) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
- (2016) David F. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer
- (2016) Tobias Maurer et al. JOURNAL OF UROLOGY
- Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
- (2016) Gillian M Duchesne et al. LANCET ONCOLOGY
- Predictors of Time to Metastasis in Castration-resistant Prostate Cancer
- (2016) Daniel M. Moreira et al. UROLOGY
- Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials
- (2016) Masahiko Nakayama et al. BMC Urology
- Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model
- (2015) Howard I. Scher et al. PLoS One
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Androgen receptor signaling in prostate cancer
- (2014) Zoran Culig et al. CANCER AND METASTASIS REVIEWS
- Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence
- (2014) P. Stattin et al. JNCI-Journal of the National Cancer Institute
- Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of circulating tumor cells in different stages of prostate cancer
- (2013) Mark Thalgott et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Advances in Androgen Receptor Targeted Therapy for Prostate Cancer
- (2013) Alia Ahmed et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
- (2013) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer
- (2013) K Miller et al. PROSTATE CANCER AND PROSTATIC DISEASES
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Targeting the androgen receptor in the management of castrationresistant prostate cancer: rationale, progress, and future directions
- (2012) R. Leibowitz–Amit et al. Current Oncology
- Androgen receptor (AR) aberrations in castration-resistant prostate cancer
- (2012) Kati K. Waltering et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer
- (2010) Matthew R. Smith et al. CANCER
- Current management of castrate-resistant prostate cancer
- (2010) S. J. Hotte et al. Current Oncology
- Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
- (2010) Michael E. Jung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More